Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH
NCT03166735
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
114
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG:
BI 1467335
DRUG:
Placebo
Sponsor
Boehringer Ingelheim